Offering

Fobi AI Announces Completion of Non-Brokered Placement

Retrieved on: 
Thursday, February 29, 2024

VANCOUVER, BC, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) (the "Company" or "Fobi"), an industry leader in harnessing AI and data intelligence to enable digital transformation, is pleased to announce that, further to its press release dated February 28, 2024, it has completed a non-brokered private placement offering (the "Offering") of 7,603,569 units of the Company ("Units") at a price per Unit of $0.07 for aggregate gross proceeds of $532,250. 

Key Points: 
  • I am deeply humbled and grateful for the overwhelming interest and support we have received for our listed issuer financing exemption (“LIFE”) offering.
  • As we reached the maximum eligible investment, we received a couple of large orders that unfortunately couldn't be accommodated within the LIFE offering.
  • Recognizing this demand, the parties involved approached us to explore the possibility of an additional private placement.
  • To download the Fobi Investor Experience Wallet Pass to get enhanced access to investor information about Fobi, please visit our Investor Experience page .

Sotera Health Announces Pricing of Secondary Offering

Retrieved on: 
Wednesday, February 28, 2024

CLEVELAND, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the pricing of its secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share, at a price to the public of $14.75 per share.

Key Points: 
  • CLEVELAND, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the pricing of its secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share, at a price to the public of $14.75 per share.
  • The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering.
  • The Company has agreed to pay certain Offering expenses consistent with its obligations under its Amended and Restated Registration Rights Agreement.
  • Barclays, RBC Capital Markets and Santander US Capital Markets LLC are acting as joint book-running managers for the Offering.

***February 28, 2024 - Redistribution of prior news release dated February 2, 2024 for wide dissemination*** Fobi AI Announces Private Placement of Units for Aggregate Gross Proceeds of Up To C$2,000,000

Retrieved on: 
Wednesday, February 28, 2024

Each Unit shall consist of one (1) common share in the capital of the Company (a “Common Share”) and one (1) common share purchase warrant (each, a “Warrant”).

Key Points: 
  • Each Unit shall consist of one (1) common share in the capital of the Company (a “Common Share”) and one (1) common share purchase warrant (each, a “Warrant”).
  • For avoidance of doubt, the Company shall not be obligated to exercise the Acceleration Right at any time.
  • There is an offering document related to the Offering that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s investor website at https://investors.fobi.ai/life-offering-subscription-agreement .
  • To download the Fobi Investor Experience Wallet Pass to get enhanced access to investor information about Fobi, please visit our Investor Experience page .

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Retrieved on: 
Wednesday, February 28, 2024

MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded Warrants” and, together with the Shares, the “Securities”).

Key Points: 
  • MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded Warrants” and, together with the Shares, the “Securities”).
  • In addition, Milestone expects to grant the underwriters a 30-day option to purchase a number of additional common shares equal to 15% of the Securities offered in the Offering.
  • All Securities to be sold in the Offering will be sold by the Company.
  • The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

WTW Prices Offering of $750,000,000 of Senior Notes

Retrieved on: 
Wednesday, February 28, 2024

LONDON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Willis Towers Watson Public Limited Company (NASDAQ: WTW) (the “Company” or “WTW”), a leading global advisory, broking and solutions company, today announced the pricing of a registered offering (the “Offering”) by Willis North America Inc. (“Willis North America”), an indirect wholly-owned subsidiary of the Company, of $750,000,000 aggregate principal amount of 5.900% senior unsecured notes due 2054 (the “notes”).

Key Points: 
  • LONDON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Willis Towers Watson Public Limited Company (NASDAQ: WTW) (the “Company” or “WTW”), a leading global advisory, broking and solutions company, today announced the pricing of a registered offering (the “Offering”) by Willis North America Inc. (“Willis North America”), an indirect wholly-owned subsidiary of the Company, of $750,000,000 aggregate principal amount of 5.900% senior unsecured notes due 2054 (the “notes”).
  • The Company expects the Offering to close on March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Willis North America intends to use the net proceeds of the Offering to (i) repay approximately $650 million aggregate principal amount of the 3.600% Senior Notes due 2024 and related accrued interest, when due, which will result in the repayment in full of the 3.600% Senior Notes due 2024, and (ii) for general corporate purposes.
  • The Offering was made pursuant to an effective shelf registration statement on file with the Securities and Exchange Commission.

Colliers International Group Inc. Completes US$300 Million Bought Deal Public Offering of Equity

Retrieved on: 
Wednesday, February 28, 2024

TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers” or the “Company”) is pleased to report that it has closed its previously announced bought deal public offering of 2,479,500 subordinate voting shares (the “Subordinate Voting Shares”), at a price of US$121.00 per Subordinate Voting Share for gross proceeds of US$300.0 million (the “Offering”) with a syndicate of underwriters led by BMO Capital Markets and J.P. Morgan as joint bookrunners, and including Mizuho, National Bank Financial, RBC Capital Markets, Scotiabank, Merrill Lynch, BTIG, LLC, CIBC Capital Markets, Goldman Sachs, Raymond James, TD Securities, Wells Fargo and Stifel Nicolaus (the “Underwriters”).

Key Points: 
  • TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (TSX and NASDAQ: CIGI) (“Colliers” or the “Company”) is pleased to report that it has closed its previously announced bought deal public offering of 2,479,500 subordinate voting shares (the “Subordinate Voting Shares”), at a price of US$121.00 per Subordinate Voting Share for gross proceeds of US$300.0 million (the “Offering”) with a syndicate of underwriters led by BMO Capital Markets and J.P. Morgan as joint bookrunners, and including Mizuho, National Bank Financial, RBC Capital Markets, Scotiabank, Merrill Lynch, BTIG, LLC, CIBC Capital Markets, Goldman Sachs, Raymond James, TD Securities, Wells Fargo and Stifel Nicolaus (the “Underwriters”).
  • Colliers has granted the Underwriters an option, exercisable at the offering price for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the Offering to cover over-allotments, if any.
  • The net proceeds of the Offering will be used to repay balances outstanding on the Company’s credit facility and are intended to create additional capacity to fund potential future acquisition opportunities and growth initiatives, and for general corporate purposes.
  • No securities regulatory authority has either approved or disapproved of the contents of this news release.

Perella Weinberg Partners Prices Upsized Public Offering of Class A Common Stock

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (the “Company” or “PWP”) (Nasdaq: PWP), a leading global independent advisory firm, today announced the pricing of its upsized public offering of 5,000,000 shares of Class A common stock at a public offering price of $12.00 per share (the “Offering”).

Key Points: 
  • NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Perella Weinberg Partners (the “Company” or “PWP”) (Nasdaq: PWP), a leading global independent advisory firm, today announced the pricing of its upsized public offering of 5,000,000 shares of Class A common stock at a public offering price of $12.00 per share (the “Offering”).
  • In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 750,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions.
  • The Offering is expected to close on March 1, 2024, subject to customary closing conditions.
  • The Offering is being made only by means of a previously filed effective shelf registration statement on Form S-3 (File No.

Optimi Announces Closing of First Tranche of Non-Brokered Private Placement

Retrieved on: 
Wednesday, February 28, 2024

The Company intends to use the net proceeds from the Offering to obtain its Drug Establishment License, facilitate commercialization, and for general working capital.

Key Points: 
  • The Company intends to use the net proceeds from the Offering to obtain its Drug Establishment License, facilitate commercialization, and for general working capital.
  • JJ Wilson and Dane Stevens, co-founders of Optimi, emphasize, “We are fully dedicated to Optimi's mission of becoming the leading end-to-end supplier of GMP psychedelics.
  • In addition to the financing, the Company also announces that specific founders have agreed to a one-year voluntary lock-up period for their founder shares.
  • This additional commitment, along with the founders' participation in the financing, emphasizes their dedication to commercializing the business and establishing sustainable markets for its products.

Sotera Health Announces Secondary Offering of Common Stock

Retrieved on: 
Tuesday, February 27, 2024

CLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share.

Key Points: 
  • CLEVELAND, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share.
  • In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,750,000 shares of common stock.
  • The Company is not offering any shares in the Offering and will not receive any of the proceeds from the Offering.
  • The Company will pay the expenses of the Offering pursuant to its obligations under its Amended and Restated Registration Rights Agreement.

West Red Lake Gold Announces a US$20 Million Private Placement of Gold Linked Notes

Retrieved on: 
Tuesday, February 27, 2024

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- West Red Lake Gold Mines Ltd. (“West Red Lake Gold” or “WRLG” or the “Company”) (TSXV: WRLG) (OTCQB: WRLGF), is pleased to announce that it has entered into an agreement with Raymond James Ltd. to act as sole bookrunner and lead agent, on behalf of a syndicate of agents (together, the “Agents”), in connection with a marketed “best efforts” private placement of units of the Company (each, a “Unit”) at a price of US$1,000 per Unit (the “Offering Price”) for gross proceeds of US$20,000,000 (the “Offering”). The Agents will have the option to sell up to an additional 15% of the Units offered, exercisable, in whole or in part, at any time up to 48 hours prior to the Closing Date (as defined below) to cover over-allotments, if any.

Key Points: 
  • Each Unit will contain gold-linked notes in the aggregate principal amount of US$1,000 (the “Notes”) and 710 common share purchase warrants (the “Warrants”).
  • Commencing January 1, 2026, the Company will cause gold to be placed in escrow on a quarterly basis into a gold trust account.
  • The Notes will amortize based on a guaranteed floor price of US$1,800 per ounce of gold (the “Floor Price”).
  • Any excess proceeds by which the gold price exceeds the Floor Price will be paid to investors as a premium.